Please assess the completion status of the following clinical trial:

Trial Title: Omeprazole and Reflux Disease - Improvement of Clinical Outcome by Genotype-adjusted Dosing

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with GERD grade A and B (mild to moderate severe disease) diagnosed by routine endoscopy will be recruited in different clinical and ambulant centres of gastroenterology; written informed consent is obligatory~* Range of Age: 20-70~* BMI: 20-30~Exclusion Criteria:~* Patients who are allergic to proton-pump inhibitors or show incompatibility~* Patients who have lactase deficiency~* Patients who have severe chronic disease~* Patients who participated in another study during the last three months~* Patients who are pregnant

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- control group (Type: ACTIVE_COMPARATOR): 3 tablets, only 20 mg omeprazole, genotype independent
- intervention group (Type: ACTIVE_COMPARATOR): 20 vs. 60 mg daily, genotype dependent

Based on this trial design, predict the completion outcome and termination type (if applicable).